Chronic Heart Failure - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Heart Failure - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Heart Failure - Pipeline Review, H1 2015', provides an overview of the Chronic Heart Failure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chronic Heart Failure Overview 9
Therapeutics Development 10
Pipeline Products for Chronic Heart Failure - Overview 10
Pipeline Products for Chronic Heart Failure - Comparative Analysis 11
Chronic Heart Failure - Therapeutics under Development by Companies 12
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 13
Chronic Heart Failure - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Chronic Heart Failure - Products under Development by Companies 17
Chronic Heart Failure - Products under Investigation by Universities/Institutes 19
Chronic Heart Failure - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
AnGes MG, Inc. 21
ARCA biopharma, Inc. 22
Bayer AG 23
Bial - Portela & Ca, S.A. 24
Celyad 25
Jiangsu Hengrui Medicine Co., Ltd. 26
Laboratoires Pierre Fabre SA 27
Les Laboratoires Servier SAS 28
Mesoblast Limited 29
Novartis AG 30
Pfizer Inc. 31
PhaseBio Pharmaceuticals, Inc. 32
Sanofi 33
Stemedica Cell Technologies, Inc. 34
Zensun (Shanghai) Sci & Tech Co., Ltd. 35
Chronic Heart Failure - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(sacubitril + valsartan) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
aliskiren fumarate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BAY-1067197 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
beperminogene perplasmid - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BIA-51058 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BR-5489 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
C3BSCQR-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
carvedilol phosphate ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cenderitide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
F-373280 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
finerenone - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
furosemide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ivabradine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Mesenchymal Stem Cells - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MPC-150IM - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Neucardin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
omecamtiv mecarbil - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PB-1046 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
rivaroxaban - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
SAR-296968 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
serelaxin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
sildenafil citrate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
vericiguat - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Chronic Heart Failure - Recent Pipeline Updates 95
Chronic Heart Failure - Dormant Projects 130
Chronic Heart Failure - Product Development Milestones 132
Featured News & Press Releases 132
Apr 15, 2015: FDA Approves Corlanor (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure 132
Mar 10, 2015: CardioCell Adds Stony Brook University to Sites Conducting a Phase IIa Clinical Trial Using Its Stem Cells for Patients With Chronic Heart Failure 133
Mar 09, 2015: An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to Launch 134
Mar 02, 2015: Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure market registration with Paediatric Investigation Plan waiver from EMA 134
Mar 02, 2015: Amgen Showcases Cardiovascular Pipeline At ACC.15 With Chronic Heart Failure Data 134
Feb 13, 2015: Novartis heart failure medicine LCZ696 granted FDA priority review 136
Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy 136
Sep 14, 2014: Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 137
Aug 27, 2014: FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 138
Jul 08, 2014: CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy to Treat Chronic Heart Failure (HF) Due to Non-Ischemic Cardiomyopathy 139
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

List of Tables

Number of Products under Development for Chronic Heart Failure, H1 2015 10
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Chronic Heart Failure - Pipeline by Amgen Inc., H1 2015 20
Chronic Heart Failure - Pipeline by AnGes MG, Inc., H1 2015 21
Chronic Heart Failure - Pipeline by ARCA biopharma, Inc., H1 2015 22
Chronic Heart Failure - Pipeline by Bayer AG, H1 2015 23
Chronic Heart Failure - Pipeline by Bial - Portela & Ca, S.A., H1 2015 24
Chronic Heart Failure - Pipeline by Celyad, H1 2015 25
Chronic Heart Failure - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 26
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 27
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2015 28
Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2015 29
Chronic Heart Failure - Pipeline by Novartis AG, H1 2015 30
Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2015 31
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 32
Chronic Heart Failure - Pipeline by Sanofi, H1 2015 33
Chronic Heart Failure - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 34
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Assessment by Combination Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2015 95
Chronic Heart Failure - Dormant Projects, H1 2015 130
Chronic Heart Failure - Dormant Projects (Contd..1), H1 2015 131